Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
Werewolf Therapeutics, Inc. (HOWL)
Company Research
Source: GlobeNewswire
Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Werewolf’s proprietary PREDATOR platform uses clinically validated protease-cleavable linkers for tumor-selective activation to improve t
Show less
Read more
Impact Snapshot
Event Time:
HOWL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOWL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOWL alerts
High impacting Werewolf Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOWL
News
- Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results [Yahoo! Finance]Yahoo! Finance
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citizens Jmp from a "strong-buy" rating to a "hold" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Citigroup Inc. from a "market outperform" rating to a "market perform" rating.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock.MarketBeat
- Werewolf Therapeutics (NASDAQ:HOWL) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
HOWL
Earnings
- 11/4/25 - Beat
HOWL
Sec Filings
- 1/16/26 - Form SCHEDULE
- 1/15/26 - Form 4
- 1/12/26 - Form 4
- HOWL's page on the SEC website